BioCatalyst

KPTI — Karyopharm Therapeutics Inc. catalysts

2 verified catalyst event(s) for Karyopharm Therapeutics Inc. (ticker KPTI). Each is linked to its official source. Verified as of 2026-09-20.

Next verified catalyst

2026-12-01 — Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DL · official source ↗

Upcoming

DateEventCompanyDrugOfficial source & verification
2026-12 (month)
in 2mo
ESTIMATED
 READOUT
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Ly
Phase 2 · Diffuse Large B-cell Lymphoma
 KPTI Karyopharm Therapeutics Inc. Selinexor, Selinexor, Selinexor ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
2026-12 (month)
in 2mo
ESTIMATED
 READOUT
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without
Phase 2/3 · Relapsed/Refractory Diffuse Large B-cell Lymphoma
 KPTI Karyopharm Therapeutics Inc. Selinexor (combination therapy), Selinex ClinicalTrials.gov ↗
✓ Source-checked 2026-09-20
Sponsor-projected date — can change
Disclaimer. Bio Catalyst Calendar is a public-events data calendar. Every date is sourced and linked to an official record (ClinicalTrials.gov, FDA / Federal Register, openFDA). It is scheduling and reference data only — NOT investment advice, a recommendation, or a buy/sell signal. Dates set by sponsors and the FDA can change; always confirm against the linked official source.